中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents

A prognostic analysis of transcatheter arterial chemoembolization combined with local ablation in treatment of recurrent liver cancer after surgery

DOI: 10.3969/j.issn.1001-5256.2022.07.021
Research funding:

Natural Science Foundation of Ningxia Province (2019AAC03192);

Key R & D Project of Ningxia Science and Technology Department (2020BEG03004);

Special Project of Science and Technology benefiting the People of Ningxia Hui Autonomous Region (2021CMG03014);

Special Project of Science and Technology benefiting the People of Ningxia Hui Autonomous Region (2021CMG03015);

Ningxia Hui Autonomous Region Science and Technology Infrastructure Construction Plan Innovation Platform Fund (2020CXPT0007)

More Information
  • Corresponding author: LU Zhenhui, zhenhuilu@hotmail.com(ORCID: 0000-0003-3509-7837)
  • Received Date: 2021-11-14
  • Accepted Date: 2021-12-20
  • Published Date: 2022-07-20
  •   Objective  To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with local ablation in the treatment of recurrent liver cancer after surgery, as well as the risk factors for prognosis.  Methods  A retrospective analysis was performed for the data of 47 patients with recurrent liver cancer after surgery who received TACE combined with local ablation in General Hospital of Ningxia Medical University from January 2017 to December 2020. The patients were followed up after local ablation to assess short-term outcome and survival. Univariate and multivariate analyses were used to investigate the factors affecting prognosis; the Kaplan-Meier model and the log-rank test were used for univariate analysis, and the Cox proportional-hazards regression model was used for multivariate analysis.  Results  At 3 months after treatment, the 47 patients with recurrent liver cancer after surgery had an overall effective rate of 89.3% and a disease control rate of 95.7%, and the overall survival rates at 6, 12, 18, and 24 months were 95.70%, 76.40%, 63.30%, and 58.00%, respectively. The univariate analysis and the Cox proportional-hazards regression analysis showed that irregularity of tumor boundary (risk ratio [RR]=3.938, 95% confidence interval [CI]: 1.709-9.073, P=0.005) and proximity of tumor to risk areas (major blood vessels and hollow visceral organs, etc.) (RR=3.202, 95% CI: 1.415-7.245, P=0.001) were associated with postoperative survival.  Conclusion  TACE combined with local ablation is an effective treatment modality for recurrent liver cancer after surgery, and irregularity of tumor boundary and proximity of tumor to risk areas (major blood vessels and hollow visceral organs, etc.) are the risk factors affecting the postoperative survival of such patients.

     

  • loading
  • [1]
    GRUTTADAURIA S, BARBERA F, CONALDI PG, et al. Clinical and molecular-based approach in the evaluation of hepatocellular carcinoma recurrence after radical liver resection[J]. Cancers (Basel), 2021, 13(3): 518. DOI: 10.3390/cancers13030518.
    [2]
    SONG Q, REN W, FAN L, et al. Long-term outcomes of transarterial chemoembolization combined with radiofrequency ablation versus transarterial chemoembolization alone for recurrent hepatocellular carcinoma after surgical resection[J]. Dig Dis Sci, 2020, 65(4): 1266-1275. DOI: 10.1007/s10620-019-05733-0.
    [3]
    PENG ZW, ZHANG YJ, LIANG HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: A prospective randomized trial[J]. Radiology, 2012, 262(2): 689-700. DOI: 10.1148/radiol.11110637.
    [4]
    DI COSTANZO GG, TORTORA R, D'ADAMO G, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial[J]. J Gastroenterol Hepatol, 2015, 30(3): 559-565. DOI: 10.1111/jgh.12791.
    [5]
    YOON SM, RYOO BY, LEE SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial[J]. JAMA Oncol, 2018, 4(5): 661-669. DOI: 10.1001/jamaoncol.2017.5847.
    [6]
    TAO Q, HE W, LI B, et al. Resection versus resection with preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma recurrence[J]. J Cancer, 2018, 9(16): 2778-2785. DOI: 10.7150/jca.25033.
    [7]
    ZHENG J, CAI J, TAO L, et al. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis[J]. Int J Surg, 2020, 83: 196-204. DOI: 10.1016/j.ijsu.2020.09.031.
    [8]
    WANG C, LIAO Y, QIU J, et al. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: A propensity score matching study[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2669-2680. DOI: 10.1007/s00432-020-03254-2.
    [9]
    LYU TS, ZOU YH, WANG J, et al. Current status of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of primary liver cancer[J]. J Clin Hepatol, 2016, 32(1): 49-55. DOI: 10.3969/j.issn.1001-5256.2016.01.007.

    吕天石, 邹英华, 王健, 等. 经肝动脉化疗栓塞术联合射频消融治疗原发性肝癌的现状[J]. 临床肝胆病杂志, 2016, 32(1): 49-55. DOI: 10.3969/j.issn.1001-5256.2016.01.007.
    [10]
    WANG T, WANG CY, LIU JY, et al. Effectiveness and safety of ultrasound-guided ablation in treatment of primary liver cancer in dangerous areas[J]. J Clin Hepatol, 2021, 37(7): 1594-1598. DOI: 10.3969/j.issn.1001-5256.2021.07.023.

    王婷, 王春妍, 刘建勇, 等. 超声引导下局部消融治疗危险区域原发性肝癌的效果及安全性分析[J]. 临床肝胆病杂志, 2021, 37(7): 1594-1598. DOI: 10.3969/j.issn.1001-5256.2021.07.023.
    [11]
    LIU YY, LAI JX. Minimally invasive interventional therapy for liver cancer[J/CD]. Chin J Hepat Surg (Electronic Edition), 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001.

    刘允怡, 赖俊雄. 肝癌微创介入治疗[J/CD]. 中华肝脏外科手术学电子杂志, 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001.
    [12]
    SHI YP, ZHAI B. Local treatment of liver cancer: Ablation or resection?[J]. J Clin Hepatol, 2021, 37(3): 506-509. DOI: 10.3969/j.issn.1001-5256.2021.03.003.

    史瑶平, 翟博. 肝癌局部治疗——消融或切除?[J]. 临床肝胆病杂志, 2021, 37(3): 506-509. DOI: 10.3969/j.issn.1001-5256.2021.03.003.
    [13]
    RUAN JQ, CHEN X, ZHANG HH, et al. Clinical effect of radio frequency ablation combined with trans catheter arterial chemoembolization in the treatment of primary liver cancer with portal vein tumor thrombus[J]. China Med Herald, 2020, 17(20): 25-28, 33. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202020008.htm

    阮健秋, 陈欣, 张红环, 等. 射频消融术联合肝动脉化疗栓塞治疗原发性肝癌伴门静脉癌栓的临床效果[J]. 中国医药导报, 2020, 17(20): 25-28, 33. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202020008.htm
    [14]
    GAO LL, QIN SX, CHEN W, et al. Efficacy of TACE combined with RFA in the treatment of mid-term primary liver cancer and its influence on serum levels of GP73, AFP and AFP-L3[J]. J Clin Exp Med, 2021, 20(13): 1388-1391. DOI: 10.3969/j.issn.1671-4695.2021.13.012.

    高磊磊, 秦帅鑫, 陈威, 等. TACE联合RFA治疗中期原发性肝癌的疗效及对患者血清GP73、AFP和AFP-L3水平的影响[J]. 临床和实验医学杂志, 2021, 20(13): 1388-1391. DOI: 10.3969/j.issn.1671-4695.2021.13.012.
    [15]
    PENG Z, WEI M, CHEN S, et al. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: A propensity score matching study[J]. Eur Radiol, 2018, 28(8): 3522-3531. DOI: 10.1007/s00330-017-5166-4.
    [16]
    ZHANG H, XU XB, HE XJ, et al. Comparison of the efficacy of combination of transcatheter arterial chemoembolization and radio frequency ablation and re-operation on postoperative recurrent primary carcinoma of liver[J]. J Xinxiang Med Coll, 2014, 31(11): 928-930. DOI: 10.7683/xxyxyxb.2014.11.018.

    张辉, 徐新保, 何晓军, 等. 肝动脉栓塞化学治疗联合射频消融与再次手术切除治疗原发性肝癌术后复发的疗效比较[J]. 新乡医学院学报, 2014, 31(11): 928-930. DOI: 10.7683/xxyxyxb.2014.11.018.
    [17]
    WANG TT. A new prognostic model of early tumor progression after local thermal ablation of hepatocellular carcinoma[D]. Tianjin: Tianjin Medical University, 2019.

    王婷婷. 肝癌局部热消融后肿瘤早期进展的预测模型[D]. 天津: 天津医科大学, 2019.
    [18]
    ZONG YY, XU H, XU W, et al. Sequential therapy of TACE followed by percutaneous microwave coagulation for early-stage primary hepatocellular carcinomas: Curative effect and prognostic factors[J]. J Intervent Radiol, 2015, 24(3): 210-214. DOI: 10.3969/j.issn.1008-794X.2015.03.007.

    宗迎迎, 徐浩, 许伟, 等. 经肝动脉化疗栓塞联合经皮微波消融序贯治疗早期肝癌的疗效及预后影响因素[J]. 介入放射学杂志, 2015, 24(3): 210-214. DOI: 10.3969/j.issn.1008-794X.2015.03.007.
    [19]
    FU Y, JI JS, TU JF, et al. The clinical application of TACE combined with RFA and sorafenib in treating recurrent hepatocellular carcinoma after surgery[J]. J Intervent Radiol, 2015, 24(12): 1067-1071. DOI: 10.3969/j.issn.1008-794X.2015.12.010.

    付元, 纪建松, 涂建飞, 等. TACE联合RFA及索拉菲尼在肝癌外科术后复发治疗中的临床应用[J]. 介入放射学杂志, 2015, 24(12): 1067-1071. DOI: 10.3969/j.issn.1008-794X.2015.12.010.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Article Metrics

    Article views (494) PDF downloads(45) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return